{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:25:51Z","timestamp":1784863551732,"version":"3.55.0"},"reference-count":38,"publisher":"Akademiai Kiado Zrt.","issue":"20","license":[{"start":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T00:00:00Z","timestamp":1684627200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,5,21]]},"abstract":"<jats:p>A SARS-CoV-2 megjelen\u00e9s\u00e9vel a myeloma multiplexben szenved\u0151k leggyakoribb\n                    hal\u00e1loz\u00e1si ok\u00e1nak sz\u00e1m\u00edt\u00f3 fert\u0151z\u0151 \u00e1gensek k\u00f6re tov\u00e1bb b\u0151v\u00fclt. Az absztrakt\n                    sz\u00f6vegez\u00e9sekor vil\u00e1gszerte domin\u00e1l\u00f3 SARS-CoV-2 omikron vari\u00e1ns (PANGO B.1.1.529)\n                    b\u00e1r kisebb val\u00f3sz\u00edn\u0171s\u00e9ggel okoz fat\u00e1lis kimenetel\u0171 fert\u0151z\u00e9st immunkompetensekben\n                    a kor\u00e1bbi delta vari\u00e1nshoz (PANGO B.1.617.2) k\u00e9pest, hat\u00e9konyabb transzmisszi\u00f3s\n                    k\u00e9pess\u00e9ge miatt az \u00e1tfert\u0151z\u00f6ttek incidenci\u00e1ja val\u00f3sz\u00edn\u0171leg nem alacsony. A\n                    COVID\u201319 s\u00falyos vagy kritikus lefoly\u00e1s\u00e1nak val\u00f3sz\u00edn\u0171s\u00e9g\u00e9t n\u00f6veli a myeloma\n                    multiplexben szenved\u0151 betegek eset\u00e9n az alapbetegs\u00e9g, annak c\u00e9lzott hematol\u00f3giai\n                    kezel\u00e9se, valamint a betegs\u00e9ghez t\u00e1rsul\u00f3 egy\u00e9b komorbidit\u00e1sok (p\u00e9ld\u00e1ul\n                    veseel\u00e9gtelens\u00e9g) okozta komplex humor\u00e1lis \u00e9s cellul\u00e1ris immunszuppresszi\u00f3. A\n                    min\u00e9l kor\u00e1bban megkezdett antivir\u00e1lis ter\u00e1pi\u00e1k, a pre- vagy posztexpoz\u00edci\u00f3s\n                    profilaxisk\u00e9nt alkalmazott monoklon\u00e1lis antitestk\u00e9sz\u00edtm\u00e9nyek, valamint a\n                    rekonvaleszcensplazma-ter\u00e1pia megakad\u00e1lyozhatja a fert\u0151z\u00e9s klinikai\n                    progresszi\u00f3j\u00e1t. M\u00edg az \u00e1tlagpopul\u00e1ci\u00f3ban a COVID\u201319-et k\u00eds\u00e9r\u0151, k\u00f6z\u00f6ss\u00e9gben\n                    szerzett koinfekci\u00f3k incidenci\u00e1ja nem magas, myeloma multiplex eset\u00e9n a l\u00e9g\u00fati\n                    v\u00edrusbetegs\u00e9geket k\u00f6vet\u0151 <jats:italic>Streptococcus pneumoniae<\/jats:italic> fert\u0151z\u00e9s kb.\n                    150-szer nagyobb es\u00e9llyel okozhat invaz\u00edv betegs\u00e9get. A modern onkohematol\u00f3giai\n                    kezel\u00e9sek hat\u00e1s\u00e1ra a myeloma multiplex m\u00e1ra kr\u00f3nikus, t\u00f6bbsz\u00f6ri relapsussal\n                    k\u00eds\u00e9rt entit\u00e1ss\u00e1 v\u00e1lt, az ebben szenved\u0151ket a fenti k\u00e9t k\u00f3rokoz\u00f3val szemben\n                    immuniz\u00e1lni sz\u00fcks\u00e9ges. Cikk\u00fcnkben citokinviharral komplik\u00e1lt COVID\u201319-ben,\n                    valamint invaz\u00edv <jats:italic>Streptococcus pneumoniae<\/jats:italic> betegs\u00e9gben szenved\u0151,\n                    majd k\u00f3rh\u00e1zi ell\u00e1t\u00e1sa sor\u00e1n <jats:italic>de novo<\/jats:italic> myeloma multiplexszel\n                    diagnosztiz\u00e1lt feln\u0151tt beteg eset\u00e9t ismertetj\u00fck, v\u00e9g\u00fcl r\u00f6viden \u00e1ttekintj\u00fck az\n                    ezzel kapcsolatos legfontosabb irodalmi adatokat. Orv Hetil. 2023; 164(20):\n                    763\u2013769.<\/jats:p>","DOI":"10.1556\/650.2023.32785","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T08:53:19Z","timestamp":1684745599000},"page":"763-769","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":2,"title":["\u201eA baj nem j\u00e1r egyed\u00fcl\u201d \u2013 de novo diagnosztiz\u00e1lt myeloma multiplex invaz\u00edv Streptococcus pneumoniae fert\u0151z\u00e9ssel citokinviharral sz\u00f6v\u0151d\u00f6tt COVID\u201319-ben"],"prefix":"10.1556","volume":"164","author":[{"given":"Dorina","family":"Kor\u00f3zs","sequence":"first","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z, Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet Budapest, Albert Fl\u00f3ri\u00e1n \u00fat 5\u20137., 1097 Magyarorsz\u00e1g"},{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Infektol\u00f3gus szakorvosk\u00e9pz\u00e9s Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Jen\u0151fi","sequence":"additional","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z, Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet Budapest, Albert Fl\u00f3ri\u00e1n \u00fat 5\u20137., 1097 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1lint Gergely","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z, Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet Budapest, Albert Fl\u00f3ri\u00e1n \u00fat 5\u20137., 1097 Magyarorsz\u00e1g"},{"name":"Semmelweis Egyetem, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika, Infektol\u00f3giai Tansz\u00e9ki Csoport Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Szl\u00e1vik","sequence":"additional","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z, Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet Budapest, Albert Fl\u00f3ri\u00e1n \u00fat 5\u20137., 1097 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Mikala","sequence":"additional","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z, Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet Budapest, Albert Fl\u00f3ri\u00e1n \u00fat 5\u20137., 1097 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","unstructured":"1 World Health Organization. Weekly epidemiological update on COVID-19 - 14 December 2022. Available from: http:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---14-december-2022 [accessed: December 20, 2022]."},{"key":"ref1","unstructured":"2 World Health Organization. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available from: http:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 [accessed: December 20, 2022]."},{"key":"ref2","unstructured":"3 Centers for Disease Control and Prevention. New SARS-CoV-2 variant of concern identified: Omicron (B.1.1.529) variant. Available from: http:\/\/www.emergency.cdc.gov\/han\/2021\/han00459.asp [accessed: December 20, 2022]."},{"key":"ref3","unstructured":"4 World Health Organization. Enhancing response to Omicron SARS-CoV-2 variant. Available from: http:\/\/www.who.int\/publications\/m\/item\/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states [accessed: December 20, 2022]."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.clinpr.2021.100130","article-title":"Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination","volume":"13","author":"5 Stampfer","year":"2022","unstructured":"5 Stampfer SD, Goldwater MS, Bujarski S, et al. Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination. Clin Infect Pract. 2022; 13: 100130.","journal-title":"Clin Infect Pract"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation","volume":"102","author":"6 Blad\u00e9","year":"1998","unstructured":"6 Blad\u00e9 J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998; 102: 1115-1123.","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116: 3724-3734. Erratum: Blood 2011; 117: 3477.","DOI":"10.1182\/blood-2011-02-335794"},{"key":"ref7","unstructured":"8 National Cancer Registry. Cancer registry statistics. [Nemzeti R\u00e1kregiszter. R\u00e1kregiszter statisztika.] Available from: http:\/\/www.stat.nrr.hu\/nrrstat\/regi\/0 [accessed: June 15, 2022]. [Hungarian]"},{"key":"ref8","unstructured":"9 National Cancer Institute. Cancer Stat Facts: Myeloma. Available from: http:\/\/www.seer.cancer.gov\/statfacts\/html\/mulmy.html [accessed: December 20, 2022]."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"10 Kyle","year":"2003","unstructured":"10 Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78: 21-33.","journal-title":"Mayo Clin Proc"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci M","year":"2009","unstructured":"11 Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009; 49: 1211-1225.","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12 Hardi A, Varga G, Nagy Zs, et al. Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime. [Hossz\u00fa t\u00e1v\u00fa progresszi\u00f3mentes t\u00fal\u00e9l\u00e9s relab\u00e1lt, refrakter myeloma multiplex tiszt\u00e1n or\u00e1lis ixazomib-lenalidomid-dexametazon kezel\u00e9s\u00e9vel.] Orv Hetil. 2021; 162: 1451-1458. [Hungarian]","DOI":"10.1556\/650.2021.32179"},{"issue":"10272","key":"ref12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"13 Van de Donk","year":"2021","unstructured":"13 Van de Donk NW, Pawlyn C, Yong KL. Multiple myeloma. Lancet 2021; 397(10272): 410-427.","journal-title":"Lancet"},{"key":"ref13","unstructured":"14 World Health Organization. Living guidance for clinical management of COVID-19. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2021-2 [accessed: December 20, 2022]."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15 K\u00e1sler M. (ed.) Handbook for the prevention and treatment of infections (COVID-19) caused by the new coronavirus (SARS-CoV-2) identified in 2020. [K\u00e1sler M. (szerk.) A 2020. \u00e9vben azonos\u00edtott \u00faj koronav\u00edrus (SARS-CoV-2) okozta fert\u0151z\u00e9sek (COVID-19) megel\u0151z\u00e9s\u00e9nek \u00e9s ter\u00e1pi\u00e1j\u00e1nak k\u00e9zik\u00f6nyve.] Emberi Er\u0151forr\u00e1sok Miniszt\u00e9riuma, Budapest, 2021. [Hungarian]","DOI":"10.22627\/2072-8107-2020-19-1-5-6"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"16 Avivi","year":"2021","unstructured":"16 Avivi I, Balaban R, Shragai T, et al. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. Br J Haematol. 2021; 195: 186-193.","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"35","author":"17 Stampfer","year":"2021","unstructured":"17 Stampfer SD, Goldwater MS, Jew S, et al. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia 2021; 35: 3534-3541.","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13045-021-01183-2","article-title":"Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls","volume":"14","author":"18 Bitoun","year":"2021","unstructured":"18 Bitoun S, Henry J, Vauloup-Fellous C, et al. Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls. J Hematol Oncol. 2021; 14: 166.","journal-title":"J Hematol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00296-022-05091-7","article-title":"Interferon-gamma release assays outcomes in healthy subjects following BNT162b2 mRNA COVID-19 vaccination","volume":"42","author":"19 Kurteva","year":"2022","unstructured":"19 Kurteva E, Vasilev G, Tumangelova-Yuzeir K, et al. Interferon-gamma release assays outcomes in healthy subjects following BNT162b2 mRNA COVID-19 vaccination. Rheumatol Int. 2022; 42: 449-456.","journal-title":"Rheumatol Int"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/bjh.18066","article-title":"Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell response","volume":"197","author":"20 Ramasamy","year":"2022","unstructured":"20 Ramasamy K, Salder R, Jeans S, et al. Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell response. Br J Haematol. 2022; 197: 293-301.","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21 Barreiro P, Sanz JC, San Rom\u00e1n J, et al. A pilot study for the evaluation of an Interferon Gamma Release Assay (IGRA) to measure T-cell immune responses after SARS-CoV-2 infection or vaccination in a unique cloistered cohort. J Clin Microbiol. 2022; 60: e0219921.","DOI":"10.1128\/jcm.02199-21"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22 Bird S, Panopoulou A, Shea RL, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021; 8: e389-e392.","DOI":"10.1016\/S2352-3026(21)00110-1"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","article-title":"A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward","volume":"13","author":"23 Wang","year":"2020","unstructured":"23 Wang B, Van Oekelen O, Mouhieddine TH, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020; 13: 94.","journal-title":"J Hematol Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.3324\/haematol.2020.262758","article-title":"Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany","volume":"105","author":"24 Engelhardt","year":"2020","unstructured":"24 Engelhardt M, Shoumariyeh K, R\u00f6sner A, et al. Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica 2020; 105: 2872-2878.","journal-title":"Haematologica"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set","volume":"136","author":"25 Chari","year":"2020","unstructured":"25 Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood 2020; 136: 3033-3040.","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26 Hultcrantz M, Richter J, Rosenbaum CA, et al. COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. Blood Cancer Discov. 2020; 1: 234-243. Erratum: Blood Cancer Discov. 2020; 1: 290.","DOI":"10.1158\/2643-3230.BCD-20-0160"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27 Ludwig H, Sonneveld P, Facon T, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021; 8: e934-e946.","DOI":"10.1016\/S2352-3026(21)00278-7"},{"key":"ref27","unstructured":"28 Centers for Disease Control and Prevention. COVID-19 vaccines for people who are moderately or severely immunocompromised. Available from: http:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html [accessed: December 20, 2022]."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29 F\u00e1bi\u00e1n \u00c1. The role of SARS-CoV-2 antibody therapy in the treatment of COVID-19. [A SARS-CoV-2-ellenes antitestekkel v\u00e9gzett ter\u00e1pia helye a COVID-19 kezel\u00e9s\u00e9ben.] Orv Hetil. 2021; 162: 2030-2039. [Hungarian]","DOI":"10.1556\/650.2021.32414"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"30 Gottlieb","year":"2022","unstructured":"30 Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022; 386: 305-315.","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12879-016-1648-2","article-title":"Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors","volume":"16","author":"31 Backhaus","year":"2016","unstructured":"31 Backhaus E, Berg S, Andersson R, et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis. 2016; 16: 367.","journal-title":"BMC Infect Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1017\/S0950268810000919","article-title":"Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies","volume":"138","author":"32 Wong","year":"2010","unstructured":"32 Wong A, Marrie TJ, Garg S, et al. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect. 2010; 138: 1804-1810.","journal-title":"Epidemiol Infect"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"33 Ludwig","year":"2021","unstructured":"33 Ludwig H, Boccadoro M, Moreau P, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2021; 35: 31-44.","journal-title":"Leukemia"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.cmi.2020.06.025","article-title":"Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting","volume":"26","author":"34 Hughes","year":"2020","unstructured":"34 Hughes S, Troise O, Donaldson H, et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020; 26: 1395-1399.","journal-title":"Clin Microbiol Infect"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35 Feh\u00e9r \u00c1, Szarvas Z, Lehoczki A, et al. Co-infections in COVID-19 patients and correlation with mortality rate. Minireview. Physiol Int. 2022; 109: 1-8.","DOI":"10.1556\/2060.2022.00015"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36 Karaba SM, Jones G, Helsel T, et al. Prevalence of co-infection at the time of hospital admission in COVID-19 patients. A multicenter study. Open Forum Infect Dis. 2021; 8: ofaa578.","DOI":"10.1093\/ofid\/ofaa578"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","article-title":"Co-infections in people with COVID-19: a systematic review and meta-analysis","volume":"81","author":"37 Lansbury","year":"2020","unstructured":"37 Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020; 81: 266-275.","journal-title":"J Infect"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.cmi.2021.11.008","article-title":"Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression","volume":"28","author":"38 Langford","year":"2022","unstructured":"38 Langford BJ, So M, Leung V, et al. Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression. Clin Microbiol Infect. 2022; 28: 491-501.","journal-title":"Clin Microbiol Infect"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/20\/article-p763.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/20\/article-p763.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/20\/article-p763.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T07:45:44Z","timestamp":1698133544000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/20\/article-p763.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,21]]},"references-count":38,"journal-issue":{"issue":"20"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32785","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,21]]}}}